Intraluminal infusion of Penta-Galloyl Glucose reduces abdominal aortic aneurysm development in the elastase rat model.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 08 03 2020
accepted: 24 05 2020
entrez: 29 8 2020
pubmed: 29 8 2020
medline: 2 10 2020
Statut: epublish

Résumé

An abdominal aortic aneurysm (AAA) is a progressive chronic dilatation of the abdominal aorta with terminally rupture when the aortic wall is so weakened that aortic wall stress exceeds wall strength. No effective medical treatment exists so far. We aimed to test whether intraluminal admission of Penta-Galloyl Glucose (PGG) treatment in a rodent AAA model could hold the potential to inhibit aneurysmal progression. Male Sprague Dawley rats had either intraluminal elastase infused for AAA induction or saline to serve as controls. In two independent experimental series, elastase was used to induce AAA followed by an intraluminal PGG (directly or by a drug eluting balloon) treatment. All rats were followed for 28 days and euthanized. In both series, maximal infrarenal aortic diameter was measured at baseline and at termination as a measure of AAA size. In series 2, maximal internally AAA diameter was followed by ultrasound weekly. AAA tissues were analyzed for elastin integrity by millers stain, collagen deposition by masson trichrome staining. In other AAA tissue samples the mRNA level of CD45, lysyloxidase (LOX), lysyloxidase like protein 1 (LOXL1) were determined by qPCR. Direct administration of PGG significantly reduced AAA expansion when compared to controls. PGG treatment resulted in a higher number and more preserved elastic fibers in the aneurysmal wall, while no significant difference was seen in the levels of CD45 and LOX mRNA levels. The drug eluting balloon (DEB) experiment showed no significant difference in AAA size observed neither macroscopically nor ultrasonically. Also the aneurysmal mRNA levels of CD45, LOX and LOXL1 were unchanged between groups. A significant reduced expansion of AAAs was observed in the PGG group, suggesting PGG as a drug to inhibit aneurysmal progression, while administration through a DEB did not show a promising new way of administration.

Sections du résumé

BACKGROUND
An abdominal aortic aneurysm (AAA) is a progressive chronic dilatation of the abdominal aorta with terminally rupture when the aortic wall is so weakened that aortic wall stress exceeds wall strength. No effective medical treatment exists so far. We aimed to test whether intraluminal admission of Penta-Galloyl Glucose (PGG) treatment in a rodent AAA model could hold the potential to inhibit aneurysmal progression.
METHOD
Male Sprague Dawley rats had either intraluminal elastase infused for AAA induction or saline to serve as controls. In two independent experimental series, elastase was used to induce AAA followed by an intraluminal PGG (directly or by a drug eluting balloon) treatment. All rats were followed for 28 days and euthanized. In both series, maximal infrarenal aortic diameter was measured at baseline and at termination as a measure of AAA size. In series 2, maximal internally AAA diameter was followed by ultrasound weekly. AAA tissues were analyzed for elastin integrity by millers stain, collagen deposition by masson trichrome staining. In other AAA tissue samples the mRNA level of CD45, lysyloxidase (LOX), lysyloxidase like protein 1 (LOXL1) were determined by qPCR.
RESULTS
Direct administration of PGG significantly reduced AAA expansion when compared to controls. PGG treatment resulted in a higher number and more preserved elastic fibers in the aneurysmal wall, while no significant difference was seen in the levels of CD45 and LOX mRNA levels. The drug eluting balloon (DEB) experiment showed no significant difference in AAA size observed neither macroscopically nor ultrasonically. Also the aneurysmal mRNA levels of CD45, LOX and LOXL1 were unchanged between groups.
CONCLUSION
A significant reduced expansion of AAAs was observed in the PGG group, suggesting PGG as a drug to inhibit aneurysmal progression, while administration through a DEB did not show a promising new way of administration.

Identifiants

pubmed: 32857766
doi: 10.1371/journal.pone.0234409
pii: PONE-D-20-06721
pmc: PMC7454949
doi:

Substances chimiques

Hydrolyzable Tannins 0
RNA, Messenger 0
pentagalloylglucose 3UI3K8W93I
Protein-Lysine 6-Oxidase EC 1.4.3.13
Pancreatic Elastase EC 3.4.21.36

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0234409

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Immunol. 2016 Jun 1;196(11):4536-43
pubmed: 27183603
Adv Biomed Res. 2014 Mar 25;3:100
pubmed: 24800189
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H1067-75
pubmed: 22904155
Br J Surg. 2015 Jul;102(8):902-6
pubmed: 25923784
Circulation. 1990 Sep;82(3):973-81
pubmed: 2144219
Circulation. 2007 Apr 3;115(13):1729-37
pubmed: 17372168
Eur J Vasc Endovasc Surg. 2016 Oct;52(4):487-499
pubmed: 27543385
Theranostics. 2016 Aug 18;6(11):1975-1987
pubmed: 27698934
Pharm Res. 2009 Sep;26(9):2066-80
pubmed: 19575286
N Engl J Med. 2014 Nov 27;371(22):2101-8
pubmed: 25427112
Ann Med Surg (Lond). 2015 Jan 14;4(1):30-5
pubmed: 25685342
J Nat Med. 2014 Jul;68(3):465-72
pubmed: 24532420
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8759-64
pubmed: 27432961
Ann Vasc Surg. 2018 Jan;46:193-204
pubmed: 29107003
Br J Surg. 2010 Jun;97(6):826-34
pubmed: 20473995
Curr Opin Cardiol. 1996 Sep;11(5):504-18
pubmed: 8889378
J Vasc Surg. 2011 Jan;53(1):28-35
pubmed: 20934838
BMC Med Imaging. 2017 Feb 14;17(1):14
pubmed: 28193267
Ann Biomed Eng. 2019 Jan;47(1):39-59
pubmed: 30298373

Auteurs

Asbjørn Sune Schack (AS)

Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark.
Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.

Jane Stubbe (J)

Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark.
Department of Cardiovascular and Renal Research, Odense University Hospital, Odense, Denmark.

Lasse Bach Steffensen (LB)

Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark.

Hend Mahmoud (H)

Department of Cardiovascular and Renal Research, Odense University Hospital, Odense, Denmark.

Malene Skaarup Laursen (MS)

Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark.
Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.

Jes Sanddal Lindholt (JS)

Centre for Individualized Medicine in Arterial Diseases, Odense University Hospital, Odense, Denmark.
Department of Cardiothoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH